BACKGROUND: Tranexamic acid (TXA) therapy is effective in reducing postoperative red blood cell (RBC) transfusion in total joint arthroplasty (TJA), yet uncertainty persists regarding comparative efficacy and safety among specific patient subgroups. We assessed the impact of a universal TXA protocol on RBC transfusion, postoperative hemoglobin (Hb), and adverse outcomes to determine whether TXA is safe and effective in TJA, both overall and in clinically relevant subgroups.
STUDY DESIGN AND METHODS:
A retrospective observational study was performed on patients undergoing TJA at our institution spanning 1 year before and after the implementation of a universal protocol to administer intravenous (IV) TXA. The primary outcome was percentage of patients transfused, and secondary outcomes were perioperative Hb and occurrence of adverse events (death, myocardial infarction, stroke, seizure, pulmonary embolism, deep vein thrombosis, and acute kidney injury ). Outcomes were compared in pre-and post-protocol groups with χ 2 analysis. Logistic regression compared risk of transfusion in pre-and post-protocol subgroups of patients with differing risk for transfusion (anemia, body mass index [BMI] , and sex).
RESULTS:
No differences were found in baseline patient characteristics across pre-and post-protocol groups (n = 1084 and 912, respectively). TXA use increased from 32.3% to 92.2% while transfusion rates decreased from 10.3% to 4.8% (p < 0.001). Postoperative Day 3 Hb increased from 95.8 to 101.4 g/L (p < 0.001). Logistic regression demonstrated reduced transfusion in post-protocol subgroups regardless of sex, anemia, or BMI (p < 0.001). No increase in adverse events was observed (p = 0.8451).
CONCLUSIONS:
Universal TXA was associated with a reduction of RBC transfusion, overall and in clinically relevant subgroups, strengthening the rationale for universal therapy.
A compelling body of literature has established the efficacy of tranexamic acid (TXA) for transfusion reduction in total joint arthroplasty (TJA). [1] [2] [3] [4] However, the previously reported use of TXA (11-46% of TJA patients) belies the published evidence of drug efficacy, possibly due to unsettled questions of drug safety. 5, 6 Further, concepts of individualized therapy may ABBREVIATIONS: BMI = body mass index; DVT = deep vein thrombosis; MI = myocardial infarction; NSQIP = National Surgical Quality Improvement Program; PE = pulmonary embolism; SAE = serious adverse event; THA = total hip arthroplasty; THK = total knee arthroplasty; TJA = total joint arthroplasty; TXA = tranexamic acid; VTE = venous thromboembolism.
lead to selective application of TXA to those deemed either at greater risk for transfusion or with greater likelihood for benefit. Although we and others have reported success with TXA applied "universally" to unselected groups of TJA patients, 6 no one has reported the comparative efficacy of TXA in relation to preexisting putative risk factors for transfusion. The importance of such a comparison may be to enable enhanced clinical decision making. The recognition of groups that benefit marginally or not all from TXA may warrant a targeted approach to TXA use, whereas the demonstration that all patients, with and without risk factors, benefit meaningfully from TXA may provide justification for universal application. To date, the reported safety data in both TJA and other patients have been reassuring [3] [4] [5] 7 and, importantly, do not point to a risk of excess harm from TXA either generally or in any identifiable subgroup. Although future such data might dissuade the practice of universal TXA administration, continued absence of evidence of harm would focus decision making on comparisons of efficacy between patients with differing risk for transfusion. The current study addresses the hypothesis that universal application of TXA is effective in reducing red blood cell (RBC) transfusion for all TJA patients. 
MATERIALS AND METHODS

Venous thromboembolism prophylaxis
During the study period, subcutaneous dalteparin (2500 units if <0 kg; 5000 units for 50-100 kg; 7500 units if >100 kg) was used in patients with normal renal function while in the hospital. Following discharge, patients received either oral rivaroxaban 10 mg daily or continued to receive dalteparin, depending on surgeon preference. Total duration of prophylaxis was from 14 days postoperative following TKA and 35 days postoperative following THA.
Transfusion management
No transfusion algorithm was used in this study. The decision for transfusion was made by the anesthesiologist and surgeon within the operating room and post-anesthesia care unit and the surgical team on the ward. The transfusion threshold for patients on the ward was near 75 g/L between 2012 and 2014. 8 Sample size calculation A sample size calculation was performed based on published and preliminary data collected in 2012. The current analysis was performed without subsequent sample size calculation after a full year of protocol utilization.
Data collection
Data were collected through a retrospective chart review using the hospital's internal database, Soarian Clinicals. For all outcomes, several elements of the electronic chart were reviewed including the operative record, anesthesia record, doctor's notes and orders, nursing notes, and blood bank records to ensure completeness and accuracy of record collection.
Statistical analysis
Statistical analysis was performed by an independent statistician at the Dalla Lana School of Public Health, University of Toronto. Comparisons of transfusion rate and postoperative Hb were made before and after initiation of the TXA protocol by χ 2 analysis. Subgroup assessment using χ 2 analysis was made based on surgery type (i.e., primary THA, primary TKA, revision THA, revision TKA). The impact of putative risk factors on transfusion rate was quantified (odds ratio [OR]) using logistic regression analysis to model transfusion risk based on age, sex, body mass index (BMI) category, surgery type, and preoperative anemia. The World Health Organization definition of anemia was used to define preoperative anemia (Hb<120 g/L for females, Hb<130 g/L for males). BMI was collapsed into four nonparametric categories: "underweight" (BMI < 20), "healthy weight" (BMI 20-24.9), "overweight" (BMI 25-29.9), and "obese" (BMI ≥ 30). Risk factors for transfusion were assessed for impact on protocol efficacy using χ 2 analysis. Logistic regression was used to describe the magnitude of protocol benefit for all possible permutations of risk factor carriage by calculating adjusted risk of transfusion pre-versus postprotocol for each permutation of risk factor status. Composite SAEs were compared by χ 2 analysis before and after protocol initiation and by assessing individual SAE rates per TXA-treated patients versus SAE rates in patients not treated with TXA by the Fisher exact test.
RESULTS
Patient characteristics
No statistically significant differences were found in demographic characteristics between the pre-protocol versus the post-protocol group (Table 1) . TXA use in the pre-protocol group was 32.3% and increased to 92.2% (p < 0.001) in the post-protocol group (Table 1) .
Overall protocol effect
Before implementing the universal TXA protocol, 112 of 1084 (10.3%) of patients were transfused 166 RBC units. Following implementation of the protocol, 44 of 912 (4.8%) of patients were transfused 93 RBC units. The overall RBC transfusion rate was significantly in the post-protocol group (10.3 vs. 4.8%, p < 0.001).
When stratified by surgery type, patients undergoing primary hip and knee surgery each had statistically significant transfusion reduction (Table 2) . Revision surgery did not retain statistical significance for transfusion avoidance; however, the study was not powered for a comparison of revision surgery, and this category had few patients. Hb values on postoperative Day 1 and 3 were higher in the post-protocol group compared with the pre-protocol group for primary joint replacement (Table 3 ; p < 0.001) but not for revision arthroplasty. The overall protocol effect is depicted in Supplemental Fig. S1 .
Effect of patient characteristics and treatment factors on transfusion rate
Logistic regression was used to examine the impact of patient and treatment factors on the OR for transfusion. The OR for transfusion in patients in the post-protocol group was 0.399 (95% confidence interval [CI], 0.271-0.586) (Fig. 1) . The categories "underweight" (BMI < 20), "healthy weight" (BMI 20-24.9), and "overweight" (BMI 25-29.9) were each associated, in descending order, with a higher OR for transfusion as compared with the "obese" (BMI ≥ 30) category. Absence of preexisting anemia was strongly associated with avoidance of transfusion (OR 0.211, 95% CI, 0.145-0.307). Although revision surgery was associated with a higher transfusion rate than primary surgery, no significant differences in transfusion rate were found between THA and TKA, either for primary or revision surgery. The independent effect of patient sex (OR 1.28, 95% CI 0.89-1.85) trended toward statistical significance; age was not associated with RBC transfusion. Assessment of the effect of TXA protocol implementation with stratification of the patient cohort by sex, preoperative Hb, and BMI are presented in Fig. 2 . Because the "obese" BMI category was the most protective against transfusion, the other BMI categories are collapsed into a single "nonobese" category for the purposes of risk factor comparison. A significant impact of TXA protocol implementation was observed regardless of patient sex, Hb, or BMI (Fig. 2) .
To predict the impact of the TXA protocol on patients having differing combinations of risk factors, adjusted transfusion rate estimates were calculated both pre-and postprotocol, along with corresponding absolute percentage reduction, for all eight permutations of the three binary risk factor categories described earlier (Figs. 3 and 4) . In Fig. 3 , each permutation of risk factors is plotted with its corresponding pre-protocol transfusion estimate and shown in descending order. The estimated absolute transfusion reduction for each category is plotted in Fig. 4 . For each permutation, a positive and statistically significant reduction was seen with a lower transfusion rate in the post-protocol era. As expected, the permutations with risk factors present were associated with higher pre-protocol transfusion For each group, the absolute difference in transfusion rate between protocol eras is shown. Negative values indicate reduced transfusion in the post-protocol era. The 95% confidence interval (CI) is stated, and for ranges that do not include "0," statistical significance (p < 0.05) is demonstrated (i.e., all patients, and primary hip and primary knee groups). estimates than those without risk factors; the permutations with stronger predictors as calculated by logistic regression (Fig. 1) showed interaction yielding higher estimates than those with weaker risk factors. Notably, the descending order of transfusion reduction estimates shown in Fig. 4 matches the descending order of pre-protocol transfusion estimates in Fig. 3 , indicating that degree of transfusion reduction was commensurate with presence and strength of preoperative risk factors.
Adverse events
SAEs experienced by patients are depicted in Fig. 5 , with comparison of pre-protocol events versus post-protocol events. Also depicted is the actual exposure to TXA for patients experiencing SAEs because not all patients in the post-protocol era received TXA, and some patients in the pre-protocol era did receive TXA. For all types of SAEs, occurrences were few and fell below published event rates.
Rates of SAEs were compared based on actual receipt of TXA and were compared by χ 2 analysis (Fisher exact test).
Differences among SAEs were not significant for total number of events (p = 0. 
DISCUSSION
Numerous investigators have demonstrated that TXA reduces transfusion in TJA. 2, 5, 20, 21 The questions that persist surrounding TXA are not so much whether it works but rather in whom to use it. 5 Answers to these questions must consider safety, efficacy, and cost, not only as applied to TJA patients as a group but with individual patient selection in mind. As Poeran et al interpreted the available evidence in 2014, "the use of tranexamic acid in patients undergoing total joint arthroplasty may have a profound . . . impact if used in appropriate candidates-that is, those at high risk for requiring blood transfusions." 5 Further, "[a]dditional studies focusing on sub-group specific effectiveness and safety . . . are needed." To our knowledge, other investigators have not compared the efficacy of TXA as applied to patients with differing risks for perioperative transfusion. Previously, our group reported that a protocol for "universal" administration of TXA was associated with transfusion reduction compared not against absence of TXA use, but rather against selective use (37% of patients in historical cohort). 8 The hypothesis ensued that TXA may be effective even for groups without risk factors for transfusion. For comparison, the use of TXA in TJA was approximately 50% Fig. 1 . Risk ratio is shown with 95% confidence interval for potential risk factors for RBC transfusion, as determined by logistic regression. Risk ratio greater than 1 indicates higher likelihood for transfusion in first-named patient group versus second-named reference group (e.g., Underweight category is more likely to receive transfusion than Obese category).
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across Ontario in 2012. In an additional cohort of more than 800,000 TJA patients from a U.S. hospital database, Poeran et al reported only 11.2% overall use. Despite this small proportion of treated patients, they also confirmed significant transfusion reduction without an increase in perioperative complications. 5 In a more current publication, Styron et al reported a remarkable increase in TXA use (from 0.6% to 37%), attributable to translational influence of contemporaneous publications. Notably, their study dealt most directly with the implementation of a modern patient blood management (PBM) strategy implemented in the preoperative care of patients, whose elements do not differ significantly from those of our own patient cohorts, both pre-and post-protocol. They confirmed the importance not only of their PBM protocol itself, but also of preoperative Hb, BMI, and TXA use as predictors of transfusion risk. They also acknowledged the ongoing dispute regarding appropriate candidacy for TXA but were unable to comment on the comparative efficacy of TXA in patient subgroups that we identified in the current study. 21 If our interpretation of the data is accepted, it is arguable that the use of TXA in their post-protocol cohort (37%) still represents an underutilization. The present study demonstrates the association of a universal TXA protocol with transfusion reduction across all patient populations (excepting those at high risk for thromboembolic disease), independent of sex, BMI, or preoperative Hb. This affirms the applicability of our other findings, discussed later, in considering whether to use TXA in various subgroups of patients. Further, the impact of multiple risk factors in the same patient on transfusion rate is both intuitive and confirmed by means of adjusted transfusion rate estimates using logistic regression. Indeed, in the preprotocol era the greatest probability for transfusion was for those patients having all three risk factors mentioned (43.9% in anemic nonobese females). Conversely, the lowest preprotocol risk of transfusion was estimated for patients without any risk factor (5.6% in nonanemic obese males). Notably, our results demonstrate that the risk of transfusion is significantly reduced in all patients regardless of risk factors. Although the largest decrease in transfusion risk was identified in patients having all three identified risk factors (19.7% absolute reduction), there was nonetheless still a significant reduction in transfusion in patients without any identifiable risk factors (3.3% absolute reduction). These results indicate that the absence of identified risk factors for transfusion reduces, but does not eliminate, clinically significant benefit from the use of TXA in THA and TKA patients, providing support for the adoption of universal rather than targeted protocols.
The practice of targeted TXA administration could possibly remain appropriate when the impact of safety is considered. However, although the present study is underpowered to show clinically significant differences in complication rates, it is nonetheless congruent with a growing body of meta-analyses and database reports, some very recent, 3, 4 that continue to report no evidence of harm with TXA use among TJA patients. 2, 5 Despite the growing body of evidence showing no increased risk of SAEs, we nonetheless suggest ongoing vigilance, particularly for thrombotic events in high-risk patients. It should be noted that much of the available data, although reassuring, comes from selected patients and cannot therefore be generalized to a "universal" patient pool. Although our protocol aimed for "universal" administration, we excluded patients with an elevated risk for thrombosis, contributing to an actual TXA administration rate of 92%, not 100%. We believe the prudent practice of excluding patients at high risk for thrombosis nonetheless leaves a very large pool of patients eligible for TXA and that this group has not as yet been shown, either as a whole or in any discernible subgroup, to be at increased risk for harm by the available literature. Accordingly, any continued rationale for targeted use of TXA, barring the emergence of new evidence of harm, rests almost completely with putative poor efficacy in identifiable low transfusion-risk subgroups. Our data show that although there is reduced efficacy among those with fewer risk factors, there remains no identifiable category of patient that does not benefit from TXA administration. We therefore recommend the adoption of a universal protocol of IV TXA administration, with the only exceptions being patients at identified increased risk for thrombotic events, based on the exclusion criteria set out in this study. Limitations of our study are to be found with the retrospective observational study design. The completion date of the study may not allow for assessment of more recent changes in patient blood management strategies. Although our study period was not associated with any formal change in the management of TJA patients, other than the protocol itself, it is possible that other unmeasured changes (improvements) in patient blood management practice over the 2-year study period may have biased our results in favor of the protocol. In this light, the very presence of a protocol dealing with transfusion reduction may have prompted unmeasurable changes in surgical technique or transfusion decision making. Although there was no attempt to standardize transfusion criteria formally, our previous observation was that the transfusion threshold in both pre-and post-protocol groups was similar (near 7.0 g/dL). 8 Our findings of higher postoperative Hb levels in the post-protocol group tends to mitigate against the impact of this limitation because any unmeasured change toward conservative transfusion thresholds would tend to produce the opposite effect (i.e., a lower postoperative Hb level). Further, it is acknowledged that 32.8% of the pre-protocol patients received TXA, and therefore it was possible only to evaluate the impact of the protocol and not, strictly speaking, the impact of TXA itself because the latter comparison would introduce bias surrounding the factors leading to pre-protocol patients receiving TXA. Although it was not possible to determine what criteria were used by individual physicians to administer TXA in the pre-protocol era, the general tendency for its use in patients at higher perceived risk for transfusion would tend to weaken, not strengthen, the ability of our study to show benefit of the protocol. Although no statistically significant differences were found in SAE rates among those receiving TXA versus those who did not, this study is underpowered to detect such differences. It is noted that in the specific case of DVT, the post-protocol group showed an increase in DVT occurring statistically more frequently than in the pre-protocol group (post hoc analysis: p = 0.03 by the Fisher exact test). Although it is acknowledged that unimagined effects of the protocol implementation other than the actual use of TXA might conceivably account for this increase, it is most likely that any means by which the protocol might influence SAEs is directly through the actual administration of TXA. Therefore, we have reported our comparison of SAEs based on actual receipt of TXA, by means of which the observed difference was statistically nonsignificant. Likewise, the threefold increase in MI in the post-protocol group was neither statistically significant based on protocol era (post hoc analysis: p = 0.34 by the Fisher exact test) nor even different at all based on receipt of TXA (two patients experiencing MI in the smaller no-TXA cohort and two patients in the larger TXA cohort). It is noted that the patients experiencing all manner of SAEs in our groups is numerically small, falling well below the numbers needed to demonstrate a statistically significant difference given the limitation of power in the study for such purpose.
Further, our reported rates of thrombotic sequelae are below previously published rates. This may represent underdetection of DVT and/or PE. Data from a large cohort of patients published in 2014, reviewing TJA from 2008 to 2010 using National Surgical Quality Improvement Program (NSQIP) data, reported venous thromboembolism (VTE) rates of 0.9% following THA and 1.9% following TKA. 22 NSQIP data are collected through chart review, using similar methods to those used in our study, and they should therefore demonstrate similar rates of thromboembolic complications. Our study reports only symptomatic VTE, similar to what would be reported through NSQIP or in other studies relying on administrative or clinical databases. This is in contrast with other prospective studies 23, 24 using routine postoperative screening tests among the symptomatic and the asymptomatic alike, which would be expected to (and do) demonstrate a higher rate of thrombotic phenomena. It is also possible that our reported rate of VTE is reduced even compared with data sources such as NSQIP owing to the effect of patients who may have presented to other institutions for treatment of complications following discharge from our tertiary referral hospital, and therefore were not discoverable by our electronic record.
CONCLUSION
The implementation of a universal TXA protocol for TJA patients was associated with statistically significant reduction in RBC transfusion and higher postoperative Day 1 and 3 Hb levels compared with a targeted approach based on individual clinicians' prerogative. No increase in adverse events was detected following implementation of the protocol. Similar benefits were observed both within primary TKA and primary THA patients, but not for revision surgery subgroups. Lower BMI, preoperative anemia, and female sex were the risk factors found in the subgroup analysis that benefited from the greatest reduction in transfusion rates, but transfusions were nonetheless reduced in patients lacking any of these three risk factors. Based on the significant reductions in transfusion rates in all subgroups of patients, we recommend consideration for the adoption of a universal TXA administration protocol for TJA patients. Although extant literature based on large well-powered meta-analyses and retrospective databases continue not to detect harm with TXA use, continued vigilance for adverse events associated with this therapy is warranted and, if found, would change the fundamental basis of this recommendation.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article.
Supplemental Fig. S1 . Implementation of a universal protocol increased tranexamic acid (TXA) use and reduced red blood cell (RBC) transfusion rate in the post-protocol cohort (p < 0.001 for both effects). Appendix S1. STROBE statement: Checklist of items that should be included in reports of cohort studies..
